PDS BIOTECHNOLOGY CORP (PDSB)

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck...

PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023

PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the fourth quarter of 2023.

PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips PDS Biotechnology (NASDAQ:PDSB) just reported results for the fourth quarter of...

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Unique mechanism of action of the combination of PDS01ADC and Versamune® results in 3-year survival of 75% and 75% overall response rate in advanced head...

PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage...

The 3 Most Undervalued Biotech Stocks to Buy in March 2024

 These 3 undervalued biotech stocks have been left behind so far but things could begin to turn around as we head into March. 

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

Preclinical research published in Vaccines demonstrates Infectimune® significantly improved quantity and quality of potent multifunctional CD4 T cells...

PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer

Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical operations leadership and commercialization experience to the...

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

PRINCETON, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage...

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “Company”), a clinical-stage...

Tuesday Sector Laggards: Waste Management, Drugs

PDS Biotech appoints Lars Boesgaard as chief financial officer (NASDAQ:PDSB)

PDS Biotechnology appoints Lars Boesgaard as CFO, succeeding Matthew Hill, to strengthen financial management and drive clinical-stage immunotherapy firm's...

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage...

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Announced 75% of ICI-naive patients alive at 36 months in the NCI-led triple Phase 2 combination trial for advanced HPV16-positive cancer patients;...

PDS Biotech reports encouraging survival data for HPV 16+ cancer therapy (PDSB)

PDS Biotech (PDSB) reported encouraging updated survival data from a Phase 2 study of a triple combination therapy for HPV 16-positive cancers. Read more here.

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months

75% of immune checkpoint inhibitor (ICI) naïve patients remain alive at 36 months; published median overall survival (OS) in similar patients is 7-11...

PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO

Combination of PDS0101 and KEYTRUDA® appears to lead to changes towards a TH1 predominant cytokine profile reported to be associated with improved killer T...

PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

First study of patients with metastatic prostate cancer to evaluate standard-of-care chemotherapy (docetaxel) combined with an antibody drug conjugate...

PDS Biotech stock gains on data for head and neck cancer drug

PDS Biotechnology (PDSB) rises after a positive data update from its Phase 2 trial for PDS0101 with Merck's Keytruda in head and neck cancer. Read more here.

PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)

Interim VERSATILE-002 data for the first-line treatment of recurrent or metastatic head and neck cancer patients who were immune checkpoint inhibitor (ICI)...

PDS Biotechnology Enters Oversold Territory (PDSB)

PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)

Study evaluated levels of circulating cell-free HPV DNA (cfDNA) in patients with locally advanced cervical cancer in the IMMUNOCERV Phase 2 clinical trial...

PDS Biotech to Present at the LD Micro Main Event XVI

PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage...

PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101

Event to be held on Tuesday, October 3 from 8:00 to 9:00 AM EDT PRINCETON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation...

PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage...

PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

PDS0202 (Infectimune® + COBRA influenza antigens) vaccination also prevented illness/weight loss Vaccine protected against replication of the virus in the...

PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023

Company to provide updated VERSATILE-002 data on combination of PDS0101 and KEYTRUDA®...

PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage...

PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update

Successful submission of final clinical protocol and supporting CMC information to FDA to initiate Phase 3 VERSATILE-003 trial in the fourth quarter...